Choloxane, powder 0.5 g

Pharmacodynamics

Ifosfamide is an alkylating cytostatic from the group of nitrogenous mustard, a derivative of oxazaphosphorins. The antitumor activity of ifosfamide is caused by alkylation of nucleophilic centers, disruption of DNA synthesis and blockage of mitotic division of tumor cells. DNA damage occurs most frequently in G1 and G2 phases of the cell cycle.

Pharmacokinetics

After IV administration, the active substance, which is a prodrug (inactive transport form), is metabolized to the pharmacologically active metabolite 4-hydroxyyphosphamide. It is activated by enzymes (phosphoamidases) of the liver and tumor tissue. In patients with liver dysfunction the activation is delayed or even reduced.

After a single IV administration of 5 g/m2, the plasma concentration decreases bioexponentially, with a T1/2 end phase of 15 h and excretion of 61% of the dose in unchanged form; At lower doses (1.6-2.4 g/m2) excretion is monoexponential, with a T1/2 of about 7 hours, and the proportion of unchanged drug in urine is reduced 4-5 times (12-18% of dose).

< br>.

Indications

Active ingredient

Composition

1 vial contains:

Active ingredients:

ifosfamide 500 mg.

In a vial of 0.5 g powder.

There is 1 vial in the carton pack.

How to take, the dosage

Ifosfamide is part of many chemotherapeutic regimens; therefore, the data in the literature should be used to guide the choice of regimen and doses in each individual case.

The drug is administered by IV drip for 30 minutes or as a 24-hour infusion. A solution with a concentration not exceeding 4% is used.

Interaction

When concomitant use with drugs causing myelotoxic, neurotoxic and nephrotoxic effects, an increased side effect is possible.

When concomitant use with inducers of microsomal liver enzymes an increase in the formation of alkylating metabolites is possible.

When used concomitantly, it increases the hypoglycemic effect of antidiabetic drugs.

Allopurinol increases myelosuppression.

Mesna reduces nephrotoxicity.

Ifosfamide may increase the skin response to radiation.

The concomitant administration of warfarin may decrease blood clotting and increase the risk of bleeding.

Special Instructions

Before the start of treatment it is necessary to sanitize foci of chronic infection and correct possible electrolyte imbalances.

When treating with the drug it is necessary to monitor the peripheral blood picture regularly (especially paying attention to the number of neutrophils and thrombocytes), laboratory parameters of liver and kidney function, as well as to analyze urine regularly for the presence of red blood cells, the appearance of which can precede the development of hemorrhagic cystitis.

Women and men should use reliable contraception during treatment and for 3 months after therapy with ifosfamide.

In patients with impaired renal function and urine flow, the incidence of toxic effects of the drug on the CNS may increase, which may require reducing the dose of ifosfamide.

In order to ensure excretion of uric acid, patients should consume sufficient fluids.

If the first signs of bladder inflammation or blood in the urine occur, therapy with ifosfamide should be stopped.

The treatment with ifosfamide may suppress natural defense mechanisms, and antibody production in the patient’s body may decrease in response to administration of vaccines.

Impact on ability to drive vehicles and other mechanisms requiring high concentration

When treating with Holoxan there may be nausea and vomiting and encephalopathy which may affect the ability to drive or operate other mechanisms. Therefore, you should abstain from driving a vehicle or other means of transport. You should also avoid working with electric tools and mechanisms.

Contraindications

With caution: hypoproteinemia, hypoalbuminemia, electrolyte imbalance, advanced age, immunosuppression, diabetes, chronic hepatic insufficiency, brain metastases, cerebral symptoms, varicella (including recent or recent cases of chickenpox).including recent or after exposure to the disease), herpes zoster, acute infectious diseases.

Side effects

Blood system: leukopenia, thrombocytopenia, anemia. The lowest number of leukocytes and platelets is observed in 7-14 days, the recovery of the blood picture occurs usually in 21 days after the end of the course.

In the digestive system: nausea and vomiting; rarely – stomatitis, liver dysfunction, usually manifested by increased liver enzymes activity and/or serum bilirubin level.

Urinary system disorders: hemorrhagic cystitis, dysuria, frequent urination and other symptoms of bladder inflammation (blood in the urine, painful urination), renal disorders (increased concentration of creatinine and urea in serum, decreased creatinine clearance. glucosuria). Proteinuria and metabolic acidosis may also be observed.

CNS disorders: disorientation, confusion, hallucinations, fatigue, agitation, encephalopathy; less frequently – dizziness; rarely – seizures, coma, peripheral polyneuropathy.

Reproductive system disorders: disorders of gland function (azoospermia, amenorrhea).

Skin and skin appendages: reversible alopecia, photosensitization.

Local reactions: redness, swelling or pain at the injection site.

Others: cardiotoxic effects, immunosuppression, infectious complications, slower wound healing rate, pulmonary symptoms (cough or shortness of breath), increased body temperature, allergic reactions.

Overdose

Symptoms: more rapid development and acute severity of the main side effects.

Treatment: symptomatic, with mandatory use of Mesna.

Pregnancy use

The drug is contraindicated in pregnancy and lactation.